203 results on '"Beninato T"'
Search Results
2. Gynecology subspecialist faculty census
- Author
-
Steffen, M.R., primary, Tummala, S., additional, Beninato, T., additional, Poulas, E., additional, Pool, A., additional, Kinyoun, M.J., additional, and Muffly, T.M., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Did COVID-19 disrupt surgery for patients with pancreatic and hepatic malignancies?
- Author
-
Manzella, A., primary, Eskander, M.F., additional, Grandhi, M.S., additional, In, H., additional, Langan, R.C., additional, Kennedy, T., additional, August, D., additional, Alexander, H.R., additional, Beninato, T., additional, and Pitt, H.A., additional
- Published
- 2023
- Full Text
- View/download PDF
4. How did COVID-19 influence use of neoadjuvant therapy before surgery for patients with HPB cancers?
- Author
-
Manzella, A., primary, Eskander, M.F., additional, Grandhi, M.S., additional, In, H., additional, Langan, R.C., additional, Kennedy, T., additional, August, D., additional, Alexander, H.R., additional, Beninato, T., additional, and Pitt, H.A., additional
- Published
- 2023
- Full Text
- View/download PDF
5. 1071P Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients
- Author
-
Prelaj, A., primary, Bottiglieri, A., additional, Provenzano, L., additional, Spagnoletti, A., additional, Mazzeo, L., additional, Miskovic, V., additional, Ganzinelli, M., additional, Lo Russo, G., additional, Ferrara, R., additional, Proto, C., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, Manglaviti, S., additional, Beninato, T., additional, Rametta, A., additional, Garassino, M.C., additional, De Braud, F.G.M., additional, Trovò, F., additional, and Pedrocchi, A., additional
- Published
- 2022
- Full Text
- View/download PDF
6. P1.15-02 Plasma microRNAs Modulation in Advanced NSCLC Patients Receiving Single Agent Immune Checkpoint Inhibitors
- Author
-
Proto, C., primary, Chiaruttini, M.V., additional, Prelaj, A., additional, Lo Russo, G., additional, Ferrara, R., additional, Manglaviti, S., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, Beninato, T., additional, Mazzeo, L., additional, Pircher, C., additional, Dumitrascu, A.D., additional, de Braud, F., additional, Segale, M., additional, Garassino, M.C., additional, Sozzi, G., additional, Porcu, L., additional, Rulli, E., additional, and Boeri, M., additional
- Published
- 2022
- Full Text
- View/download PDF
7. 1056P KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC
- Author
-
Bottiglieri, A., primary, Provenzano, L., additional, Spagnoletti, A., additional, Mazzeo, L., additional, Ganzinelli, M., additional, Lo Russo, G., additional, Ferrara, R., additional, Proto, C., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, Manglaviti, S., additional, Beninato, T., additional, Garassino, M.C., additional, Filosa, J., additional, Di Guida, G., additional, De Braud, F.G.M., additional, Viscardi, G., additional, Della Corte, C.M., additional, and Prelaj, A., additional
- Published
- 2022
- Full Text
- View/download PDF
8. 1079P Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations
- Author
-
Beninato, T., primary, Brambilla, M., additional, Pircher, C.C., additional, Mazzeo, L., additional, Rametta, A., additional, Manglaviti, S., additional, De Toma, A., additional, Galli, G., additional, Prelaj, A., additional, Ferrara, R., additional, Proto, C., additional, Lo Russo, G., additional, Ganzinelli, M., additional, Di Mauro, R., additional, Di Nucci, A., additional, Garassino, M.C., additional, Marchetti, P., additional, De Braud, F.G.M., additional, and Occhipinti, M., additional
- Published
- 2022
- Full Text
- View/download PDF
9. EP08.01-006 Using Real World data to build effective predictive machine learining models for NSCLC patients treated with immune-based therapy
- Author
-
prelaj, A., primary, Galli, E.G., additional, Pesenti, M., additional, Viscardi, G., additional, Bottiglieri, A., additional, Marinacci, R., additional, Pedica, B., additional, Proto, C., additional, Ferrara, R., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, Manglaviti, S., additional, Galli, G., additional, Mazzeo, L., additional, Beninato, T., additional, Pircher, C.C., additional, Di Mauro, M.R., additional, Ganzinelli, M., additional, Di Nucci, A., additional, Dumitrascu, A.D., additional, Di Gregorio, S., additional, De Braud, F.M.G., additional, Garassino, M.C., additional, Restelli, M., additional, Lo Russo, G., additional, Trovo', F., additional, and Pedrocchi, A.L.G., additional
- Published
- 2022
- Full Text
- View/download PDF
10. 1057P Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
- Author
-
Ferrara, R., primary, Lo Russo, G., additional, Ciniselli, C.M., additional, Di Gregorio, S., additional, Calareso, G., additional, Bassani, B., additional, Proto, C., additional, Prelaj, A., additional, De Toma, A., additional, Occhipinti, M., additional, Brambilla, M., additional, Manglaviti, S., additional, Mazzeo, L., additional, Beninato, T., additional, Ganzinelli, M., additional, De Braud, F.G.M., additional, Garassino, M.C., additional, Colombo, M.P., additional, Verderio, P., additional, and Sangaletti, S., additional
- Published
- 2022
- Full Text
- View/download PDF
11. EP08.02-046 Activity of OsimeRTInib in NSCLC with Uncommon EGFR Mutations: Retrospective Observational Multicenter Study (ARTICUNO)
- Author
-
Pizzutilo, E.G., primary, Agostara, A.G., additional, Oresti, S., additional, Signorelli, D., additional, Giannetta, L.G., additional, Stabile, S., additional, Lauricella, C., additional, Amatu, A., additional, Brambilla, M., additional, Lo Russo, G., additional, Proto, C., additional, Mazzeo, L., additional, Beninato, T., additional, Siringo, M., additional, Giusti, R., additional, Filetti, M., additional, Genova, C., additional, Barletta, G., additional, Russano, M., additional, Di Fazio, G.R., additional, Tosoni, E., additional, Metro, G., additional, Pilotto, S., additional, Carta, A., additional, Mazzoni, F., additional, Roca, E., additional, Gelibter, A.J., additional, Gori, S., additional, Berardi, R., additional, Cerea, G., additional, Sartore-Bianchi, A., additional, and Siena, S., additional
- Published
- 2022
- Full Text
- View/download PDF
12. EP07.01-021 Clinical and Biochemical Profiling of Pleural Mesothelioma Patients Treated With Immunotherapy
- Author
-
Occhipinti, M., primary, Tacchetto, A., additional, Beninato, T., additional, Pircher, C.C., additional, Mazzeo, L., additional, Manglaviti, S., additional, De Toma, A., additional, Galli, G., additional, Prelaj, A., additional, Ferrara, R., additional, Proto, C., additional, Lo Russo, G., additional, Ganzinelli, M., additional, Di Nucci, A., additional, Grande, I., additional, Rinaldi, A., additional, Platania, M., additional, Garassino, M.C., additional, Marchetti, P., additional, de Braud, F.M., additional, and Brambilla, M., additional
- Published
- 2022
- Full Text
- View/download PDF
13. MA10.07 Phase II Trial of Sunitinib in Patients with Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines - STYLE Trial (NCT03449173)
- Author
-
Proto, C., primary, Galli, G., additional, Manglaviti, S., additional, Lo Russo, G., additional, Ganzinelli, M., additional, Galli, F., additional, Musca, M., additional, Rulli, E., additional, Di Mauro, R., additional, Mella, G., additional, Lucarelli, A., additional, Paggio, A., additional, Valleggi, S., additional, Ballatore, Z., additional, Maso, A. Dal, additional, Perrino, M., additional, Chella, A., additional, Sbrana, A., additional, Prelaj, A., additional, Ferrara, R., additional, Occhipinti, M., additional, Brambilla, M., additional, De Toma, A., additional, Mazzeo, L., additional, Beninato, T., additional, Pircher, C., additional, de Braud, F., additional, Pasello, G., additional, Petrini, I., additional, Berardi, R., additional, Garassino, M., additional, and Zucali, P., additional
- Published
- 2022
- Full Text
- View/download PDF
14. Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
- Author
-
Ferrara, R, Lo Russo, G, Ciniselli, Cm, Gregorio, S, Calareso, G, Bassani, B, Proto, C, Prelaj, A, De Toma, A, Occhipinti, M, Brambilla, M, Manglaviti, S, Mazzeo, L, Beninato, T, Ganzinelli, M, De Braud, Fgm, Garassino, Mc, Colombo, Mp, Verderio, P, and Sangaletti, S
- Published
- 2022
15. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with novel actionable oncogenic driver alterations
- Author
-
Beninato, T, Brambilla, M, Pircher, Cc, Mazzeo, L, Rametta, A, Manglaviti, S, De Toma, A, Galli, G, Prelaj, A, Ferrara, R, Proto, C, Lo Russo, G, Ganzinelli, M, Di Mauro, R, Di Nucci, A, Garassino, Mc, Marchetti, P, De Braud, Fgm, and Occhipinti, M
- Published
- 2022
16. KRAS and LKB1 mutation conferring prognostic and predictive role on liquid biopsy in advanced NSCLC
- Author
-
Bottiglieri, A, Provenzano, L, Spagnoletti, A, Mazzeo, L, Ganzinelli, M, Lo Russo, G, Ferrara, R, Proto, C, De Toma, A, Brambilla, M, Occhipinti, M, Manglaviti, S, Beninato, T, Garassino, Mc, Filosa, J, Di Guida, G, De Braud, Fgm, Viscardi, G, Della Corte, Cm, and Prelaj, A
- Published
- 2022
17. Trustworthy artificial intelligence models using real-world and circulating genomics data for the prediction of immunotherapy efficacy in non-small cell lung cancer patients
- Author
-
Prelaj, A, Bottiglieri, A, Provenzano, L, Spagnoletti, A, Mazzeo, L, Miskovic, V, Ganzinelli, M, Lo Russo, G, Ferrara, R, Proto, C, De Toma, A, Brambilla, M, Occhipinti, M, Manglaviti, S, Beninato, T, Rametta, A, Garassino, Mc, De Braud, Fgm, Trovo, F, and Pedrocchi, A
- Published
- 2022
18. Radical Antegrade Modular Pancreatosplenectomy (RAMPS): Does Adrenalectomy Alter Outcomes?
- Author
-
Davis, C., primary, Beninato, T., additional, Laird, A., additional, Grandhi, M., additional, Beane, J., additional, Pitt, S., additional, and Pitt, H., additional
- Published
- 2022
- Full Text
- View/download PDF
19. P40.08 Bone-Targeted Agents Improve Survival in High Bone Tumor Burden Advanced Non-Small-Cell-Lung Cancer Patients Treated With PD-(L)1 Inhibitors
- Author
-
Manglaviti, S., primary, Bini, M., additional, Apollonio, G., additional, Galli, G., additional, Labianca, A., additional, Zecca, E., additional, Brambilla, M., additional, Occhipinti, M., additional, Proto, C., additional, Prelaj, A., additional, Signorelli, D., additional, De Toma, A., additional, Viscardi, G., additional, Beninato, T., additional, Zattarin, E., additional, Mazzeo, L., additional, Galli, E., additional, Ganzinelli, M., additional, De Braud, F.G.M., additional, Garassino, M.C., additional, Lo Russo, G., additional, and Ferrara, R., additional
- Published
- 2021
- Full Text
- View/download PDF
20. P50.06 First-Line Therapy in NSCLC harbouring EGFR or HER2 Exon 20 Insertion Mutation. Hunting for the Best Candidate
- Author
-
Prelaj, A., primary, Bottiglieri, A., additional, Lo Russo, G., additional, Ferrara, R., additional, Galli, G., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, Manglaviti, S., additional, Beninato, T., additional, Zattarin, E., additional, Apollonio, G., additional, Massa, G., additional, Mazzeo, L., additional, Galli, E., additional, Dumitrascu, D., additional, Ganzinelli, M., additional, Gallucci, R., additional, Di Mauro, R., additional, Vitale, S., additional, Braud, F.G.M. De, additional, Garassino, M.C., additional, and Proto, C., additional
- Published
- 2021
- Full Text
- View/download PDF
21. P40.19 Efficacy and Toxicity of Third-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer
- Author
-
Beninato, T., primary, Manglaviti, S., additional, Zattarin, E., additional, Apollonio, G., additional, Galli, E., additional, Bini, M., additional, Sposetti, C., additional, Massa, G., additional, Bottiglieri, A., additional, Ganzinelli, M., additional, Proto, C., additional, Ferrara, R., additional, Prelaj, A., additional, Galli, G., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, De Braud, F.G.M., additional, Garassino, M.C., additional, and Lo Russo, G., additional
- Published
- 2021
- Full Text
- View/download PDF
22. 695P Drug-drug interactions between pazopanib and proton pump inhibitors may significantly affect clinical outcome of patients affected by metastatic renal cell carcinoma
- Author
-
Del Re, M., primary, Brighi, N., additional, Rizzo, M., additional, Paolieri, F., additional, Rebuzzi, S.E., additional, Beninato, T., additional, Crucitta, S., additional, Mercinelli, C., additional, Gri, N., additional, Puglisi, S., additional, Verzoni, E., additional, Bleve, S., additional, Cucchiara, F., additional, Procopio, G., additional, Fornarini, G., additional, Galli, L., additional, Porta, C.G., additional, De Giorgi, U., additional, and Danesi, R., additional
- Published
- 2021
- Full Text
- View/download PDF
23. 1236P Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
- Author
-
Prelaj, A., primary, Bottiglieri, A., additional, Galli, E., additional, Lo Russo, G., additional, Ferrara, R., additional, Galli, G., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, Manglaviti, S., additional, Beninato, T., additional, Zattarin, E., additional, Apollonio, G., additional, Ganzinelli, M., additional, Gallucci, R., additional, Di Mauro, R.M., additional, de Braud, F., additional, Torri, V., additional, Garassino, M.C.C., additional, and Proto, C., additional
- Published
- 2021
- Full Text
- View/download PDF
24. 1327P Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)
- Author
-
Manglaviti, S., primary, Bini, M., additional, Apollonio, G., additional, Zecca, E., additional, Labianca, A., additional, Galli, G., additional, Brambilla, M., additional, Occhipinti, M., additional, Proto, C., additional, Prelaj, A., additional, Signorelli, D., additional, De Toma, A., additional, Viscardi, G., additional, Beninato, T., additional, Zattarin, E., additional, Galli, E., additional, Garassino, M.C.C., additional, de Braud, F.G.M., additional, Lo Russo, G., additional, and Ferrara, R., additional
- Published
- 2021
- Full Text
- View/download PDF
25. 1311P The role of inflammatory biomarkers in advanced non-small cell lung cancer patients treated with chemo-immunotherapy
- Author
-
Zattarin, E., primary, Manglaviti, S., additional, Galli, E., additional, Apollonio, G., additional, Beninato, T., additional, Mazzeo, L., additional, Massa, G., additional, Bottiglieri, A., additional, Ganzinelli, M., additional, Proto, C., additional, Ferrara, R., additional, Prelaj, A., additional, Galli, G., additional, De Toma, A., additional, Brambilla, M., additional, Occhipinti, M., additional, Garassino, M.C.C., additional, De Braud, F.G.M., additional, and Lo Russo, G., additional
- Published
- 2021
- Full Text
- View/download PDF
26. 2203P Uncovering prognostic transcriptomic differences in epithelioid malignant pleural mesothelioma
- Author
-
Occhipinti, M., Brambilla, M., Ambrosini, P., Pannone, A., Zanella, C., Leone, A.G., Leporati, R., Fotia, G., Di Mauro, R., Ianza, A., Manglaviti, S., Beninato, T., Mazzeo, L., Proto, C., Prelaj, A., Percio, S., De Braud, F.G.M., Lo Russo, G., Generali, D., and Ganzinelli, M.
- Published
- 2023
- Full Text
- View/download PDF
27. 1355P Evaluation of the role of variant allele frequency in EGFR mutated non-small cell lung cancer treated with first line osimertinib
- Author
-
Brambilla, M., Lorenzini, D., Occhipinti, M., Manglaviti, S., Beninato, T., Mazzeo, L., Agnelli, L., Leporati, R., Zanella, C., Leone, A.G., Fotia, G., Prelaj, A., Lo Russo, G., Grande, I., Tamborini, E., Perrone, F., Ganzinelli, M., Pruneri, G., De Braud, F.G.M., and Proto, C.
- Published
- 2023
- Full Text
- View/download PDF
28. Immunometabolism of circulating neutrophils in hyperprogressive disease (HPD) upon first-line PD-1/PD-L1 inhibitors (ICI) alone or in combination with platinum-based chemotherapy (PCT) in non-small cell lung cancer (NSCLC) patients (pts)
- Author
-
Ferrara, R, Jachetti, E, Calareso, G, Brambilla, M, Lo Russo, G, Proto, C, Prelaj, A, Signorelli, D, Galli, G, De Toma, A, Occhipinti, M, Manglaviti, S, Labianca, A, Ganzinelli, M, Spano, Sm, Molino, G, Martinetti, A, Greco, Fg, Bini, M, Beninato, T, de Braud, F, Colombo, Mp, Garassino, Mc, and Sangaletti, S
- Published
- 2021
29. 133P Drug-drug interactions (DDIs) in non-small cell lung cancer during chemotherapy-immunotherapy treatment
- Author
-
Occhipinti, M., primary, Brambilla, M., additional, Galli, G., additional, Manglaviti, S., additional, Prelaj, A., additional, Ferrara, R., additional, De Toma, A., additional, Beninato, T., additional, Zattarin, E., additional, Proto, C., additional, Lo Russo, G., additional, Gelibter, A.J., additional, Simmaco, M., additional, Garassino, M.C., additional, and Marchetti, P., additional
- Published
- 2021
- Full Text
- View/download PDF
30. 184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)
- Author
-
Manglaviti, S., primary, Galli, G., additional, Bini, M., additional, Labianca, A., additional, Zecca, E., additional, Brambilla, M., additional, Occhipinti, M., additional, Proto, C., additional, Prelaj, A., additional, Signorelli, D., additional, De Toma, A., additional, Viscardi, G., additional, Beninato, T., additional, Zattarin, E., additional, Ganzinelli, M., additional, de Braud, F.G.M., additional, Garassino, M.C., additional, Lo Russo, G., additional, and Ferrara, R., additional
- Published
- 2021
- Full Text
- View/download PDF
31. 68P OncoMutational ratio on ctDNA: A potential novel biomarker in NSCLC
- Author
-
Ambrosini, P., Provenzano, L., Bottiglieri, A., Spagnoletti, A., Di Guida, G., Mazzeo, L., Beninato, T., Leporati, R., Occhipinti, M., Brambilla, M., Manglaviti, S., Ganzinelli, M., Miskovic, V., Proto, C., Dumitrascu, A.D., De Braud, F.G.M., Corte, C.M. Della, Russo, G. Lo, Viscardi, G., and Prelaj, A.
- Published
- 2023
- Full Text
- View/download PDF
32. 1182P Baseline neutrophil-lymphocyte ratio and its variations after adjuvant radiotherapy predict clinical survival outcomes in locally advanced Merkel cell carcinoma (MCC)
- Author
-
Torchio, M., primary, Corti, F., additional, Manca, P., additional, Prinzi, N., additional, Platania, M., additional, Maurichi, A., additional, Mattavelli, I., additional, Patuzzo, R., additional, Bedini, N., additional, Milione, M., additional, Cattaneo, L., additional, Beninato, T., additional, Prisciandaro, M., additional, Raimondi, A., additional, Pagani, F., additional, Colombo, E., additional, Coppa, J., additional, Di Bartolomeo, M., additional, de Braud, F.G., additional, and Pusceddu, S., additional
- Published
- 2020
- Full Text
- View/download PDF
33. Incidental positive lymph nodes in patients with papillary thyroid cancer is independently associated with recurrent disease
- Author
-
Kluijfhout, WP, Drake, FT, Pasternak, JD, Beninato, T, Vriens, MR, Shen, WT, Gosnell, JE, Liu, C, Suh, I, and Duh, Q-Y
- Subjects
Adult ,Male ,recurrence ,Papillary ,Oncology and Carcinogenesis ,Kaplan-Meier Estimate ,Thyroid Cancer ,incidental lymph nodes ,ATA guidelines ,Humans ,papillary thyroid cancer ,Thyroid Neoplasms ,Oncology & Carcinogenesis ,Proportional Hazards Models ,Retrospective Studies ,Cancer ,Incidence ,Carcinoma ,Middle Aged ,Neoplasm Recurrence ,Local ,Lymphatic Metastasis ,Thyroidectomy ,Lymph Node Excision ,Neck Dissection ,Female - Abstract
Background and objectivesPathological examination occasionally reveals incidental central lymph nodes metastasis (iLNM) after thyroidectomy for patients with papillary thyroid cancer (PTC) who did not undergo compartment-orientated lymphadenectomy. We aimed to investigate the risk of recurrence for patients with iLNM.MethodsWe conducted a retrospective review of all patients undergoing total thyroidectomy for PTC (January 2000 to January 2010). Patients with distant metastases, central- or lateral neck dissection and pre-operative suspicious lymph nodes (by ultrasound or clinical examination) were excluded. The association between iLNM and recurrent disease was investigated using Kaplan-Meier survival estimates and Cox proportional hazards analysis.Results225/1000 patients had incidental nodes after total thyroidectomy for PTC. 183 were node-negative and 42 had iLNM. Mean age was 46 years and 201 (89%) were women. Mean number of resected nodes was 2.3. Disease recurred in 8/183 (4.4%) of patients with N0 versus 7/42 (17%) with iLNM. After adjusting for other factors, iLNM was independently associated with recurrent disease (hazard ratio = 4.01 [95% CI 1.21-13.3]).ConclusionsPositive incidental lymph nodes are independently associated with recurrent disease in patients with PTC. These patients should therefore be monitored more carefully.
- Published
- 2017
34. STYLE (NCT03449173) a phase II Trial of Sunitinib in patients with type B3 Thymoma or Thymic Carcinoma in second and further lines
- Author
-
Proto, C., Manglaviti, S., Lo Russo, G., Musca, M., Galli, G., Imbimbo, M., Perrino, M., Cordua, N., Rulli, E., Ballatore, Z., Maso, A. Dal, Chella, A., Sbrana, A., Prelaj, A., Ferrara, R., Occhipinti, M., Brambilla, M., De Toma, A., Mazzeo, L., Beninato, T., Signorelli, D., Massa, G., Greco, F.G., Calareso, G., Miliziano, D., Di Mauro, R.M., Mella, G., Lucarelli, A., Paggio, A., Galli, F., Torri, V., de Braud, F.G.M., Pasello, G., Petrini, I., Berardi, R., Ganzinelli, M., Garassino, M., and Zucali, P.
- Abstract
Thymic malignancies are rare tumors with few therapeutic options. The STYLE trial was aimed to evaluate activity and safety of sunitinib in advanced/recurrent type B3 thymoma (T) and thymic carcinoma (TC).
- Published
- 2023
- Full Text
- View/download PDF
35. Reoperation Rates After Initial Thyroid Lobectomy for Patients with Thyroid Cancer: A National Cohort Study.
- Author
-
Kheng M, Manzella A, Chao JC, Laird AM, and Beninato T
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Aged, Neoplasm Recurrence, Local, United States, Cohort Studies, Neck Dissection trends, Thyroid Gland surgery, Retrospective Studies, Thyroid Neoplasms surgery, Thyroidectomy trends, Reoperation statistics & numerical data
- Abstract
Introduction: The 2015 American Thyroid Association (ATA) guidelines recommended thyroid lobectomy (TL) as an alternative to total thyroidectomy (TT) for the surgical treatment of low-risk differentiated thyroid cancer. Increasing use of TL has since been reported despite concerns for an increased risk of disease recurrence and need for reoperation. This study sought to compare reoperation rates among patients who underwent initial TL or TT for malignancy, characterize trends at centers based on operative volume, and examine factors associated with reoperation. Methods: We queried the Vizient Clinical Data Base for TL and TT performed preguideline change (pre-GC = 2013-2015) and postguideline change (post-GC = 2016-2021). Reoperations included reoperative thyroid surgery (RTS) and neck dissection (ND); timing was defined as early (≤180 days), thought to indicate inadequacy of initial operative choice, or late (>180 days), suggesting potential disease recurrence. Results: Of 65,627 patients, 31.8% underwent initial TL and 68.2% underwent initial TT; TL increased from 21.4% of total cases pre-GC to 37.0% post-GC ( p < 0.001). Among TL patients, early RTS declined from 33.9% to 14.2% and ND declined from 0.8% to 0.4% ( p < 0.001). Among TT patients, early RTS remained 0.2%, while ND increased from 0.4% to 0.7% ( p < 0.001). TL-associated late RTS declined from 2.0% to 1.7%, while ND increased from 0.6% to 0.8% ( p = 0.17). In TT patients, both late RTS and ND increased, from 0.2% to 0.3% ( p = 0.04) and 1.7% to 2.1% ( p < 0.01), respectively. There was no difference in the late reoperation rate for TL compared with TT post-GC (+0.2%, p = 0.18). TL volume grew annually by 12.5% [8.9-16.2%] at high-volume centers (HVCs) and 8.3% [5.6-11.1%] at low-volume centers (LVCs). TL-associated reoperations at HVCs declined annually by 12.6% [5.6-19.0%] and 10.8% [2.7-18.1%] at LVCs. Uninsured status and more recent initial operation were associated with an increased risk of late reoperation (HR = 1.84 [1.06-3.20] and HR = 1.30 [1.24-1.36], respectively). The type of index operation performed, however, was not predictive of late reoperation. Conclusions: The rate of early reoperations declined for TL after the 2015 ATA guideline release, but late reoperations remained unchanged despite a significant shift in practice patterns towards initial lobectomy. Patients appear to be receiving less aggressive, guideline-concordant care without a significant increase in the late reoperation rate for TL compared with TT.
- Published
- 2024
- Full Text
- View/download PDF
36. Operative trends for pancreatic and hepatic malignancies during the COVID-19 pandemic.
- Author
-
Manzella A, Ecker BL, Eskander MF, Grandhi MS, In H, Kravchenko T, Langan RC, Kennedy T, Alexander HR, Beninato T, and Pitt HA
- Subjects
- Humans, United States epidemiology, Male, Female, Middle Aged, Neoadjuvant Therapy statistics & numerical data, Neoadjuvant Therapy trends, Aged, Pandemics, Retrospective Studies, SARS-CoV-2, Adult, COVID-19 epidemiology, Pancreatic Neoplasms surgery, Pancreatic Neoplasms epidemiology, Liver Neoplasms surgery, Liver Neoplasms epidemiology
- Abstract
Background: The COVID-19 pandemic disrupted routine health care, including many elective and non-cancer operations in the United States. Most hepato-pancreato-biliary malignancy patients require outpatient imaging, tissue sampling, and staging, and many undergo neoadjuvant therapy before operative intervention. The aims of this study were to evaluate the effect of the COVID-19 pandemic on hepato-pancreato-biliary oncologic operations and to determine whether trends in neoadjuvant therapy were altered by the pandemic., Methods: Adult patients in the United States undergoing oncologic operations for pancreatic, primary and secondary hepatic malignancies, with or without neoadjuvant therapy, were extracted from the Vizient Clinical Data Base. Control chart analysis was used to plot trends over time and to determine whether changes were statistically significant. Wilcoxon rank-sum tests also compared monthly operative volume from pre-pandemic (12 month) and pandemic (28 months) periods., Results: A total of 36,553 patients were identified over 40 months. Mean monthly pancreatic oncologic operations were unaffected by the pandemic (P = .257). Operations for pancreatic oncologic operations with prior neoadjuvant therapy increased throughout the pandemic (P = .002). Oncologic operations for primary and secondary hepatic malignancies were significantly reduced for 4 and 2 months, respectively, at the beginning of the pandemic but returned to their pre-pandemic baseline within 4 months (P = .169 and P = .598)., Conclusion: Pancreatic operation volumes for cancer did not change, but pancreatic operations after neoadjuvant therapy continued to increase during the pandemic. Operations for hepatic malignancy were transiently disrupted but quickly normalized. These observations suggest that surgery for hepato-pancreato-biliary malignancies was prioritized during the pandemic., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Association of Medicaid expansion with access to thyroidectomy for benign disease at high-volume centers.
- Author
-
Manzella A, Kheng M, Chao J, Laird AM, and Beninato T
- Subjects
- Humans, United States, Female, Male, Middle Aged, Adult, Insurance Coverage statistics & numerical data, Retrospective Studies, Healthcare Disparities statistics & numerical data, Healthcare Disparities economics, Medicaid statistics & numerical data, Thyroidectomy statistics & numerical data, Thyroidectomy economics, Hospitals, High-Volume statistics & numerical data, Health Services Accessibility statistics & numerical data, Thyroid Diseases surgery
- Abstract
Background: Insurance-based disparities in access to thyroidectomy are well established. Patients undergoing thyroidectomy by high-volume surgeons have fewer complications and better postoperative outcomes. The aim of this study was to evaluate the association of Medicaid expansion with access to high-volume centers for thyroidectomy for benign disease., Methods: The Vizient Clinical Data Base was queried for adult operations for benign thyroid disease from 2010 to 2019. Centers were sorted by volume into quartiles. Difference-in-difference analysis evaluated changes in insurance populations in expansion and non-expansion states after Medicaid expansion. Odds of patients undergoing operations in the 4 volume quartiles after stratifying by insurance and Medicaid expansion status were calculated., Results: A total of 82,602 patients underwent operations at 364 centers. Expansion states increased Medicaid coverage in all volume quartiles compared to non-expansion states after Medicaid expansion (Q1, +4.87%, Q2, +5.35%, Q3, +8.57%, Q4, +4.62%, P < .002 for all). After Medicaid expansion, Medicaid patients had higher odds of undergoing operation at lower volume hospitals compared to the highest volume centers in both expansion states (Q1, ref, Q2, 1.82, Q3, 1.76, Q4, 1.67, P < .001) and non-expansion states (Q1, ref, Q2, 1.54, Q3, 2.04, Q4, 1.44, P < .001). Privately insured patients were most likely to undergo their operation at the highest volume centers in all states (E: Q1, ref, Q2, 0.78, Q3, 0.74, Q4, 0.66, P < .001; NE: Q1, ref, Q2, 0.89, Q3, 0.58, Q4, 0.85, P < .001)., Conclusion: Medicaid expansion increased Medicaid coverage in expansion states, but Medicaid patients in both expansion and non-expansion states were less likely to be operated on at the highest volume centers compared to privately insured patients. Persistent barriers to accessing high-volume care still exists for Medicaid patients., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Which Ultrasound Characteristics Predict Lymphatic Spread of Papillary Thyroid Cancer?
- Author
-
Kravchenko T, Chen V, Hsu D, Manzella A, Kheng M, Laird AM, Simon M, Trooskin S, and Beninato T
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Adult, Aged, Sensitivity and Specificity, Biopsy, Fine-Needle, Thyroid Cancer, Papillary pathology, Thyroid Cancer, Papillary diagnostic imaging, Thyroid Neoplasms diagnostic imaging, Thyroid Neoplasms pathology, Lymphatic Metastasis diagnostic imaging, Lymphatic Metastasis pathology, Ultrasonography methods, Lymph Nodes diagnostic imaging, Lymph Nodes pathology, Predictive Value of Tests
- Abstract
Introduction: The 2015 American Thyroid Association guidelines recommend lymph node mapping US in patients with definitive cytological evidence of thyroid cancer. Suspicious lymph node features on imaging including enlarged size (>1 cm in any dimension), architectural distortion, loss of fatty hilum, and microcalcifications often prompt evaluation with fine needle aspiration. There is no universally agreed upon model for determining which ultrasound characteristics most strongly correlate with metastatic disease., Methods: A retrospective review of patients with confirmed papillary thyroid cancer (PTC) undergoing lymph node mapping ultrasound from 2013 to 2019 was performed. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were calculated for each individual ultrasound characteristic as well as for characteristic combinations., Results: Data from 119 lymph nodes were included. Malignant lymph nodes were more likely to be enlarged (71% versus 61%, P < 0.001) and to have each individual suspicious feature. Loss of fatty hilum had the highest sensitivity (89%) but was not specific (19%) for metastatic disease. Architectural distortion was found to have the highest specificity (87%). A combination of the four features was found to have higher specificity (97%) and PPV (88%) than any individual feature or combination of two/three features., Conclusions: A combination of four sonographic features correlates with metastatic PTC to lymph nodes and has the highest specificity and PPV for malignancy. A risk stratification model based on these features may lead to better classification of ultrasound findings in PTC patients with concern for nodal metastases., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: a SEER Database Analysis of Mucinous and non-Mucinous Histologies.
- Author
-
Tsagkalidis V, Choe JK, Beninato T, Eskander MF, Grandhi MS, In H, Kennedy TJ, Langan RC, Maggi JC, Pitt HA, Alexander HR, and Ecker BL
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Survival Rate, Follow-Up Studies, Prognosis, Neoplasm Recurrence, Local pathology, Neoplasm Recurrence, Local surgery, Neoplasm Staging, Adult, Appendiceal Neoplasms pathology, Appendiceal Neoplasms surgery, Appendiceal Neoplasms mortality, SEER Program, Adenocarcinoma, Mucinous surgery, Adenocarcinoma, Mucinous pathology, Adenocarcinoma, Mucinous mortality, Colectomy, Appendectomy, Adenocarcinoma surgery, Adenocarcinoma pathology, Adenocarcinoma mortality
- Abstract
Background: Mucinous appendiceal adenocarcinomas (MAA) and non-mucinous appendiceal adenocarcinomas (NMAA) demonstrate differences in rates and patterns of recurrence, which may inform the appropriate extent of surgical resection (i.e., appendectomy versus colectomy). The impact of extent of resection on disease-specific survival (DSS) for each histologic subtype was assessed., Patients and Methods: Patients with resected, non-metastatic MAA and NMAA were identified in the Surveillance, Epidemiology, and End Results database (2000-2020). Multivariable models were created to examine predictors of colectomy for each histologic subtype. DSS was calculated using Kaplan-Meier estimates and examined using Cox proportional hazards modeling., Results: Among 4674 patients (MAA: n = 1990, 42.6%; NMAA: n = 2684, 57.4%), the majority (67.8%) underwent colectomy. Among colectomy patients, the rate of nodal positivity increased with higher T-stage (MAA: T1: 4.6%, T2: 4.0%, T3: 17.1%, T4: 21.6%, p < 0.001; NMAA: T1: 6.8%, T2: 11.4%, T3: 25.6%, T4: 43.8%, p < 0.001) and higher tumor grade (MAA: well differentiated: 7.7%, moderately differentiated: 19.2%, and poorly differentiated: 31.3%; NMAA: well differentiated: 9.0%, moderately differentiated: 20.5%, and 44.4%; p < 0.001). Nodal positivity was more frequently observed in NMAA (27.6% versus 16.4%, p < 0.001). Utilization of colectomy was associated with improved DSS for NMAA patients with T2 (log rank p = 0.095) and T3 (log rank p = 0.018) tumors as well as moderately differentiated histology (log rank p = 0.006). Utilization of colectomy was not associated with improved DSS for MAA patients, which was confirmed in a multivariable model for T-stage, grade, and use of adjuvant chemotherapy [hazard ratio (HR) 1.00, 95% confidence interval (CI) 0.81-1.22]., Conclusions: Colectomy was associated with improved DSS for patients with NMAA but not MAA. Colectomy for MAA may not be required., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
40. Unleashing precision: A review of targeted approaches in pleural mesothelioma.
- Author
-
Occhipinti M, Brambilla M, Di Liello R, Ambrosini P, Lobianco L, Leporati R, Salvarezza M, Vitiello F, Marchesi S, Manglaviti S, Beninato T, Mazzeo L, Proto C, Prelaj A, Ferrara R, Della Corte CM, Lo Russo G, de Braud F, Ganzinelli M, and Viscardi G
- Subjects
- Humans, Immune Checkpoint Inhibitors therapeutic use, Mesothelioma, Malignant drug therapy, Mesothelioma, Malignant pathology, Mesothelioma, Malignant genetics, Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Precision Medicine methods, Pleural Neoplasms drug therapy, Pleural Neoplasms genetics, Pleural Neoplasms pathology, Molecular Targeted Therapy methods, Mesothelioma drug therapy, Mesothelioma genetics, Mesothelioma pathology, Mesothelioma metabolism
- Abstract
This review delves into the intricate landscape of pleural mesothelioma (PM), emphasizing the need for nuanced therapeutic strategies. While platinum-based chemotherapy remains a cornerstone, the advent of immune checkpoint inhibitors (ICIs), notably through the Checkmate 743 trial, has reshaped treatment paradigms. Challenges persist due to patient heterogeneity and a lack of specific biomarkers. Targeting genotypic and phenotypic alterations emerges as a promising avenue, demanding precision oncology in this rare disease. CDKN2A loss, prevalent in PM, may respond to CDK4/6 inhibitors. Defects in MMR and HR suggest tailored approaches with ICI or PARP inhibitors, respectively. Ongoing trials explore novel inhibitors and promising targets like mesothelin. Implementing these strategies requires overcoming challenges in patient selection, combination therapies, biomarker identification, and cost considerations. Collaboration is crucial for transforming these insights into impactful clinical interventions, heralding the era of personalized and precision medicine for PM., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
41. Concomitant Administration of VEGFR Tyrosine Kinase and Proton Pump Inhibitors May Impair Clinical Outcome of Patients With Metastatic Renal Cancer.
- Author
-
Del Re M, Crucitta S, Brighi N, Kinspergher S, Mercinelli C, Rizzo M, Conteduca V, Rebuzzi SE, Beninato T, Venturi G, Doni L, Verzoni E, Puglisi S, Landriscina M, Porta C, Manfredi F, Caffo O, De Giorgi U, Fogli S, and Danesi R
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Aged, Treatment Outcome, Adult, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Aged, 80 and over, Drug Interactions, Proton Pump Inhibitors administration & dosage, Proton Pump Inhibitors adverse effects, Proton Pump Inhibitors therapeutic use, Kidney Neoplasms drug therapy, Kidney Neoplasms pathology, Indazoles administration & dosage, Indazoles adverse effects, Carcinoma, Renal Cell drug therapy, Sunitinib administration & dosage, Sunitinib adverse effects, Sunitinib therapeutic use, Pyrimidines adverse effects, Pyrimidines administration & dosage, Sulfonamides administration & dosage, Sulfonamides adverse effects, Sulfonamides therapeutic use, Pyridines adverse effects, Pyridines administration & dosage, Pyridines therapeutic use, Anilides adverse effects, Anilides administration & dosage, Protein Kinase Inhibitors adverse effects, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors therapeutic use
- Abstract
Introduction: The administration of proton pump inhibitors (PPIs) is a common practice to reduce gastro-esophageal adverse events associated with drug treatments but may impair absorption and exposure to oncology drugs. This study investigated the effect of concomitant administration of PPIs and pazopanib, sunitinib and cabozantinib on survival of patients with metastatic clear cell renal carcinoma (mRCC)., Patients and Methods: Total 451 patients receiving pazopanib, sunitinib and cabozantinib as first line treatment were enrolled in this retrospective study. Patients were defined as "no concomitant PPIs (PPI-)" if no PPIs were administered during TKIs, and as "concomitant PPIs (PPI+)" if the administration of PPIs was at least 75% of the time during which TKIs were given., Results: Eighty patients administered pazopanib were PPI- and 86 PPI+; no difference in PFS was observed (10.7 vs. 11.9 months, P = .79). If patients were stratified as short (n = 89) and long (n = 77) responders, there was a significant difference in terms of PFS in PPI+ (n = 47) versus PPI- (n = 30) in long responders, being 24.7 versus 38 months (P = .04), respectively. In the sunitinib cohort, no significant difference of PFS in PPI+ (n = 102) versus PPI- (n = 131) was found, being 11.3 versus 18.1 months, respectively (P=0.15). In the cabozantinib cohort, there was a statistically significant difference in PFS of PPI+ versus PPI- (6 months vs. not reached, P = .04). No correlation with adverse events was found., Conclusions: This study demonstrates an association between PPIs and impaired PFS in mRCC patients given pazopanib and cabozantinib and recommends caution on their concomitant use., Competing Interests: Disclosure CP acted as a consultant and/or a speaker for Angelini Pharma, Biorek, BMS, Eisai, General Electric, Ipsen, Medendi, and MSD, and as a protocol steering committee member for BMS, Eisai, and MSD. MR received honoraria as a speaker/consultant by Astra Zeneca, MSD, BMS, Janssen, Merck and Gilead. MDR received fees from Astellas, AstraZeneca, Celgene, Novartis, Pfizer, Bio-Rad, Janssen, Sanofi-Aventis, Roche, and Ipsen; RD reports receiving speaker bureau/advisor's fee from Ipsen, Novartis, Pfizer, Sanofi Genzyme, AstraZeneca, Janssen, Gilead, Lilly, Gilead, and EUSA Pharma. All other authors have declared no conflicts of interest., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
42. Patterns in the Reporting of Aggressive Histologic Subtypes in Papillary Thyroid Cancer.
- Author
-
Lee YJ, Egan CE, Greenberg JA, Marshall T, Tumati A, Finnerty BM, Beninato T, Zarnegar R, Fahey TJ 3rd, and Romero Arenas MA
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Aged, United States epidemiology, Retrospective Studies, Databases, Factual statistics & numerical data, Thyroid Cancer, Papillary pathology, Thyroid Cancer, Papillary mortality, Thyroid Neoplasms pathology, Thyroid Neoplasms mortality, Thyroid Neoplasms epidemiology
- Abstract
Introduction: The tall cell, columnar, and diffuse sclerosing subtypes are aggressive histologic subtypes of papillary thyroid cancer (PTC) with increasing incidence, yet there is a wide variation in reporting. We aimed to identify and compare factors associated with the reporting of these aggressive subtypes (aPTC) to classic PTC (cPTC) and secondarily identify differences in outcomes., Methods: The National Cancer Database was utilized to identify cPTC and aPTC from 2004 to 2017. Patient and facility demographics and clinicopathologic variables were analyzed. Independent predictors of aPTC reporting were identified and a survival analysis was performed., Results: The majority of aPTC (67%) were reported by academic facilities. Compared to academic facilities, all other facility types were 1.4-2.0 times less likely to report aPTC (P < 0.05). Regional variation in reporting was noted, with more cases reported in the Middle Atlantic, despite there being more total facilities in the South Atlantic and East North Central regions. Compared to the Middle Atlantic, all other regions were 1.4-5 times less likely to report aPTC (P < 0.001). Patient characteristics including race and income were not associated with aPTC reporting. Compared to cPTC, aPTC had higher rates of aggressive features and worse 5-y overall survival (90.5% versus 94.5%, log rank P < 0.001)., Conclusions: Aggressive subtypes of PTC are associated with worse outcomes. Academic and other facilities in the Middle Atlantic were more likely to report aPTC. This suggests the need for further evaluation of environmental or geographic factors versus a need for increased awareness and more accurate diagnosis of these subtypes., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
43. Racial disparities in rates of invasiveness of resected intraductal papillary mucinous neoplasms in the United States.
- Author
-
Allen WE, Greendyk JD, Alexander HR, Beninato T, Eskander MF, Grandhi MS, In H, Kennedy TJ, Langan RC, Maggi JC, Moore DF, Pitt HA, De S, Haider SF, and Ecker BL
- Subjects
- Humans, United States epidemiology, Aged, Pancreatectomy, Pancreatic Ducts surgery, Neoplasm Invasiveness, Retrospective Studies, Pancreatic Neoplasms surgery, Pancreatic Neoplasms pathology, Carcinoma, Pancreatic Ductal, Neoplasms, Cystic, Mucinous, and Serous surgery
- Abstract
Background: Racial and ethnic disparities have been observed in the multidisciplinary management of pancreatic ductal adenocarcinoma. Intraductal papillary mucinous neoplasm is the most common identifiable precursor to pancreatic ductal adenocarcinoma, where early surgical intervention before the development of an invasive intraductal papillary mucinous neoplasm improves survival. The association of race/ethnicity with the risk of identifying invasive intraductal papillary mucinous neoplasms during resection has not been previously defined., Methods: The American College of Surgeons National Quality Improvement Program targeted pancreatectomy database (2014-2021) was queried for patients with race/ethnicity data who underwent resection of an intraductal papillary mucinous neoplasm. Backward Wald logistic regression modeling (P ≤ 0.05 for entry; P > .10 for removal) was used to identify independent predictors of invasion., Results: A total of 4,505 cases of resected intraductal papillary mucinous neoplasms were identified, with 923 (20.5%) demonstrating invasive intraductal papillary mucinous neoplasms. The cohort of individuals other than non-Hispanic Whites were significantly more likely to have invasive intraductal papillary mucinous neoplasms (White, 19.9%; Black, 24.2%; Asian, 23.7%; Hispanic, 22.6%; P = .026). Such disparity could not be explained by greater comorbidity, as non-White patients were significantly younger (age <65 years: 41.7% vs 33.2%, P < .001) and had better physical status (American Society of Anesthesiologists score ≤2: 28.8% vs 25.2%, P = .053). After controlling for clinicodemographic variables, being an individual of race/ethnicity other than White was independently associated with higher odds of invasive intraductal papillary mucinous neoplasms (odds ratio, 1.280; 95% confidence interval, 1.046-1.566; P = .017). No differences in postoperative morbidity were observed., Conclusion: In a national cohort of patients with resected intraductal papillary mucinous neoplasms, individuals who identified as being of race/ethnicity other than White were significantly more likely to have invasive intraductal papillary mucinous neoplasms during surgical resection., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
44. Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.
- Author
-
Miceli R, Eriksson H, Lo Russo G, Alfieri S, Moksnes Bjaanæs M, Pietrantonio F, De Cecco L, Prelaj A, Proto C, Franzén J, McDonnell D, Berenguer Pina JJ, Beninato T, Mazzeo L, Giannatempo P, Verzoni E, Crown J, Helland Å, and Eustace A
- Subjects
- Humans, Female, Male, Prospective Studies, Sex Factors, Incidence, Immunotherapy adverse effects, Immunotherapy methods, Drug-Related Side Effects and Adverse Reactions epidemiology, Drug-Related Side Effects and Adverse Reactions etiology, Drug-Related Side Effects and Adverse Reactions diagnosis, Observational Studies as Topic, Neoplasms drug therapy, Immune Checkpoint Inhibitors adverse effects
- Abstract
Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in relation to sex- differentiation and their association with gender-specific factors are limited., Aims: The primary objective of the G-DEFINER study is to compare the irAEs incidence in female and male patients who undergo ICI treatment. Secondary objectives are: to compare the irAEs incidence in pre- and postmenopausal female patients; to compare the irAEs incidence in female and male patients according to different clinical and gender-related factors (lifestyle, psychosocial, and behavioral factors). Exploratory objectives of the study are to compare and contrast hormonal, gene-expression, SNPs, cytokines, and gut microbiota profiles in relation to irAEs incidence in female and male patients., Methods and Results: The patients are recruited from Fondazione IRCCS Istituto Nazionale dei Tumori, Italy, St Vincent's University Hospital, Ireland, Oslo University Hospital, Norway, and Karolinska Insitutet/Karolinska University Hospital, Sweden. The inclusion of patients was delayed due to the Covid pandemic, leading to a total of 250 patients recruited versus a planned number of 400 patients. Clinical and translational data will be analyzed., Interpretation: The expected outcomes are to improve the management of cancer patients treated with ICIs, leading to more personalized clinical approaches that consider potential toxicity profiles. The real world nature of the trial makes it highly applicable for timely irAEs diagnosis.
- Published
- 2024
- Full Text
- View/download PDF
45. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
- Author
-
Leporati R, Miliziano D, Beninato T, Mazzeo L, Manglaviti S, Brambilla M, Occhipinti M, Prelaj A, Proto C, and Lo Russo G
- Abstract
Introduction: Several anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have been developed for the treatment of echinoderm microtubule-associated protein-like 4 (EML4)-ALK-rearranged non-small cell lung cancer (NSCLC), with the newer generation agents brigatinib, alectinib and lorlatinib showing prolonged responses. With the increasing number of target therapies available, the optimal sequence is yet to be defined, as resistance profiles may evolve over time and in response to sequential ALK inhibitors. Therefore, ALK-targeted strategies may be personalized based upon the presence of specific ALK resistance mutations., Methods: Here, we report on the case of a patient who has been treated with a sequence of three ALK TKIs after receiving diagnosis of ALK-rearranged metastatic NSCLC in 2015 and gained further benefit upon lorlatinib rechallenge after the acquisition of the G1202R resistance mutation to second generation TKIs., Results and Conclusion: In this case, the first ALK resistance mutation detected after progression on first line TKI, the I1171N, is a common resistance mutation after alectinib and confers sensitivity to brigatinib, that the patient received afterwards with a long-term disease stability. The second ALK resistance mutation detected after a chemotherapy interval, the G1202R, is the most common resistance mutation after second generation ALK TKIs and has been associated with sensitivity to third generation TKIs, such as lorlatinib. This case of a patient with EML4-ALK-rearranged NSCLC shows that sequential treatment with next-generation ALK TKIs, including rechallenge, can induce profound remissions, even in heavily pretreated patients, and that ALK-targeted strategies may be personalized by considering the presence of distinct ALK resistance mutations., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
46. Which Localizing Strategy is the Most Cost-Effective in Reoperative Primary Hyperparathyroidism?
- Author
-
Gazivoda V, Prioli KM, Li AC, Pizzi L, Laird AM, and Beninato T
- Subjects
- Humans, Cost-Benefit Analysis, Technetium Tc 99m Sestamibi, Parathyroidectomy, Four-Dimensional Computed Tomography methods, Parathyroid Glands surgery, Hyperparathyroidism, Primary surgery
- Abstract
Introduction: 2%-10% of patients with primary hyperparathyroidism (PHPT) who undergo parathyroidectomy develop persistent/recurrent disease. The aim of this study was to determine which preoperative localization method is most cost-effective in reoperative PHPT., Methods: Clinical decision analytic models comparing cost-effectiveness of localizing studies in reoperative PHPT were constructed using TreeAge Pro. Cost and probability assumptions were varied via Probabilistic Sensitivity Analysis (PSA) to test the robustness of the base case models., Results: Base case analysis of model 1 revealed ultrasound (US)-guided fine-needle aspiration with PTH assay as most cost-effective after localizing US. This was confirmed on PSA of model 1. Model 2 showed four-dimensional computed tomography (4D-CT) as most cost-effective after negative US. If not localized by US, on PSA, 4D-CT was the next most cost-effective test., Conclusions: US-guided FNA with PTH is the most cost-effective confirmatory test after US localization. 4D-CT should be considered as the next best test after negative US., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
47. Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence.
- Author
-
Lee-Saxton YJ, Egan CE, Bratton BA, Thiesmeyer JW, Greenberg JA, Marshall TE, Tumati A, Romero-Arenas M, Beninato T, Zarnegar R, Scognamiglio T, Fahey TJ 3rd, and Finnerty BM
- Abstract
Context: The significance of low mitotic activity in papillary thyroid cancer (PTC) is largely undefined., Objective: We aimed to determine the behavioral landscape of PTC with low mitotic activity compared to that of no- and high-mitotic activity., Methods: A single-institution consecutive series of PTC patients from 2018-2022 was reviewed. Mitotic activity was defined as no mitoses, low (1-2 mitoses/2 mm2) or high (≥3 mitoses/2 mm2) per the World Health Organization. The 2015 American Thyroid Association risk stratification was applied to the cohort, and clinicopathologic features were compared between groups. For patients with ≥6 months follow-up, Cox regression analyses for recurrence were performed., Results: 640 PTCs were included - 515 (80.5%) no mitotic activity, 110 (17.2%) low mitotic activity, and 15 (2.3%) high mitotic activity. Overall, low mitotic activity exhibited rates of clinicopathologic features including vascular invasion, gross extrathyroidal extension, and lymph node metastases in between those of no- and high-mitotic activity. PTCs with low mitotic activity had higher rates of intermediate- and high-risk ATA risk stratification compared to those with no mitotic activity (p < 0.001). Low mitotic activity PTCs also had higher recurrence rates (15.5% vs. 4.5%, p < 0.001). Low mitotic activity was associated with recurrence, independent of the ATA risk stratification (HR 2.96; 95% CI 1.28-6.87, p = 0.01)., Conclusions: Low mitotic activity is relatively common in PTC and its behavior lies within a spectrum between no- and high-mitotic activity. Given its association with aggressive clinicopathologic features and recurrence, low mitotic activity should be considered when risk stratifying PTC patients for recurrence., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
48. APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
- Author
-
Prelaj A, Ganzinelli M, Provenzano L, Mazzeo L, Viscardi G, Metro G, Galli G, Agustoni F, Corte CMD, Spagnoletti A, Giani C, Ferrara R, Proto C, Brambilla M, Dumitrascu AD, Inno A, Signorelli D, Pizzutilo EG, Brighenti M, Biello F, Bennati C, Toschi L, Russano M, Cortellini A, Catania C, Bertolini F, Berardi R, Cantini L, Pecci F, Macerelli M, Emili R, Bareggi C, Verderame F, Lugini A, Pisconti S, Buzzacchino F, Aieta M, Tartarone A, Spinelli G, Vita E, Grisanti S, Trovò F, Auletta P, Lorenzini D, Agnelli L, Sangaletti S, Mazzoni F, Calareso G, Ruggirello M, Greco GF, Vigorito R, Occhipinti M, Manglaviti S, Beninato T, Leporati R, Ambrosini P, Serino R, Silvestri C, Zito E, Pedrocchi ACL, Miskovic V, de Braud F, Pruneri G, Lo Russo G, Genova C, and Vingiani A
- Subjects
- Humans, Artificial Intelligence, Translational Research, Biomedical, Prospective Studies, Retrospective Studies, Leukocytes, Mononuclear, Biomarkers, Therapies, Investigational, Lung Neoplasms drug therapy, Biological Products therapeutic use
- Abstract
Introduction: Despite several therapeutic efforts, lung cancer remains a highly lethal disease. Novel therapeutic approaches encompass immune-checkpoint inhibitors, targeted therapeutics and antibody-drug conjugates, with different results. Several studies have been aimed at identifying biomarkers able to predict benefit from these therapies and create a prediction model of response, despite this there is a lack of information to help clinicians in the choice of therapy for lung cancer patients with advanced disease. This is primarily due to the complexity of lung cancer biology, where a single or few biomarkers are not sufficient to provide enough predictive capability to explain biologic differences; other reasons include the paucity of data collected by single studies performed in heterogeneous unmatched cohorts and the methodology of analysis. In fact, classical statistical methods are unable to analyze and integrate the magnitude of information from multiple biological and clinical sources (eg, genomics, transcriptomics, and radiomics)., Methods and Objectives: APOLLO11 is an Italian multicentre, observational study involving patients with a diagnosis of advanced lung cancer (NSCLC and SCLC) treated with innovative therapies. Retrospective and prospective collection of multiomic data, such as tissue- (eg, for genomic, transcriptomic analysis) and blood-based biologic material (eg, ctDNA, PBMC), in addition to clinical and radiological data (eg, for radiomic analysis) will be collected. The overall aim of the project is to build a consortium integrating different datasets and a virtual biobank from participating Italian lung cancer centers. To face with the large amount of data provided, AI and ML techniques will be applied will be applied to manage this large dataset in an effort to build an R-Model, integrating retrospective and prospective population-based data. The ultimate goal is to create a tool able to help physicians and patients to make treatment decisions., Conclusion: APOLLO11 aims to propose a breakthrough approach in lung cancer research, replacing the old, monocentric viewpoint towards a multicomprehensive, multiomic, multicenter model. Multicenter cancer datasets incorporating common virtual biobank and new methodologic approaches including artificial intelligence, machine learning up to deep learning is the road to the future in oncology launched by this project., Competing Interests: Disclosures Arsela Prelaj certifies that all conflicts of interest reported can be considered outside the present paper: consulting or advisory role for BMS, AstraZeneca; had travel, accommodations, or other expenses paid or reimbursed by Roche, Italfarmaco; principal investigator of Spectrum Pharmaceuticals. Alessandra Laura Giulia Pedrocchi holds shares of Agade srl. Giuseppe Lo Russo has received fees for acting as a consultant from Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, Amgen, Sanofi, Italfarmaco, Pfizer; has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Roche, Novartis, BMS, MSD, AstraZeneca, Takeda, Amgen, Sanofi, has received support for attending meetings and/or travel from Roche, BMS, MSD; has participated on data safety monitoring board or advisory board for Roche, Novartis, BMS, MSD, AstraZeneca, Sanofi, has acted as principal investigator in sponsored clinical trials for Roche, Novartis, BMS, MSD, AstraZeneca, GSK, Amgen, Sanofi. Rossana Berardi has received fees for acting as a consultant, for lectures and/or for participating to advisory board from BI, EISAI, GSK, Italfarmaco, Otsuka, Lilly, MSD; has received funding to Institution from AZ, BMS, Pfizer, Novartis, Roche; AMGEN. Giulia Galli declares the following conflicts of interest: Italpharma (advisory board); Roche (travel accommodation); Astra Zeneca, BMS, MSD (honoraria for lectures). Federica Bertolini has received consultant fees from MSD, Astra-Zeneca, Lilly, Eisai, Sanofi and speakers fee from BMS, MSD, Astra Zeneca. Filippo de Braud reports a patent for PCT/IB2020/055956 pending and a patent for IT201900009954 pending; and Roche, EMD Serono, NMS Nerviano Medical Science, Sanofi, MSD, Novartis, Incyte, BMS, Menarini Healthcare Research & Pharmacoepidemiology, Merck Group, Pfizer, Servier, AMGEN, Incyte. No disclosures were reported by the other authors., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
49. Does Hospital Operative Volume Influence the Outcomes of Patients After Heated Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis?
- Author
-
Chatani PD, Manzella A, Gribkova YY, Ecker BL, Beninato T, Kennedy T, Pitt HA, and Alexander HR
- Subjects
- Humans, Female, Retrospective Studies, Hyperthermic Intraperitoneal Chemotherapy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hospitals, Cytoreduction Surgical Procedures adverse effects, Combined Modality Therapy, Survival Rate, Peritoneal Neoplasms pathology, Hyperthermia, Induced, Appendiceal Neoplasms pathology
- Abstract
Background: For some cancer operations, center volume is associated with improved patient outcomes. Whether this association is true for cytoreductive surgery/heated intraperitoneal chemotherapy (CRS/HIPEC) is unclear. Given the rapidly expanding use of CRS/HIPEC, the aim of this analysis was to determine whether a volume-outcome relationship exists for this strategy., Methods: The Vizient Clinical Database® was queried for CRS/HIPEC cases from January 2020 through December 2022. Low-, medium-, and high-volume designations were made by sorting hospitals by case volume and creating equal tertiles based on total number of cases. Analysis was performed via one-way ANOVA with post-hoc Tukey test, as indicated., Results: In the 36-month study period, 5165 cases were identified across 149 hospitals. Low- (n = 113), medium- (n = 25), and high-volume (n = 11) centers performed a median of 4, 21, and 47 cases per annum, respectively. Most cases were performed for appendiceal (39.3%) followed by gynecologic neoplasms (20.4%). Groups were similar with respect to age, gender, race, comorbidities, and histology. Low-volume centers were more likely to utilize the ICU post-operatively (59.6% vs. 40.5% vs. 36.3%; p = 0.02). No differences were observed in morbidity (9.4% vs. 7.1% vs. 9.0%, p = 0.71), mortality (0.9% vs. 0.6% vs. 0.7%, p = 0.93), length of stay (9.3 vs. 9.4 vs. 10 days, p = 0.83), 30-day readmissions (5.6% vs. 5.6% vs. 5.6%, p = 1.0), or total cost among groups., Conclusions: No association was found between CRS/HIPEC hospital volume and post-operative outcomes. These data suggest that in academic medical centers with HIPEC programs, outcomes for commonly treated cancers are not associated with hospital volume., (© 2023. Society of Surgical Oncology.)
- Published
- 2024
- Full Text
- View/download PDF
50. Effects of the COVID-19 pandemic on endocrine operations in the United States.
- Author
-
Manzella A, Kravchenko T, Kheng M, Chao J, Laird AM, Pitt HA, and Beninato T
- Subjects
- Humans, United States epidemiology, Pandemics, Hospitals, Thyroid Gland, COVID-19 epidemiology, Endocrine Surgical Procedures
- Abstract
Background: The COVID-19 pandemic disrupted the United States (US) healthcare system. Endocrine operations are predominantly elective and were likely affected. Therefore, our aim was to determine the effect of the pandemic on endocrine operations., Study Design: The Vizient Clinical Data Base® was examined for cases from 1/2019-12/2022 using ICD10 and CPT codes for thyroid, parathyroid, and adrenal operations. Control chart analysis identified trends in operative volume. Negative binomial regression was utilized to analyze demographic trends., Results: Monthly volumes for all operations from 515 hospitals decreased at the beginning of 2020, except for operations for adrenal malignancy. Inpatient operations (Thyroid -17.1%, Parathyroid -20.9%, p < 0.001 for both) experienced more significant and longer lasting disruptions than outpatient operations (Thyroid -2.6%, p = 0.883, Parathyroid -9.1%, p = 0.098)., Conclusions: The COVID-19 pandemic disrupted endocrine operations across the US. While all adrenal operations and outpatient thyroid and parathyroid operations have returned to pre-pandemic levels, inpatient operations for thyroid and parathyroid remain decreased., Competing Interests: Declaration of competing interest This article has not been published previously and is not under consideration for publication elsewhere. All authors have no conflicts of interest and agree to participation and publication., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.